

The information in the press release is intended for investors.

Isofol terminates liquidity guarantee agreement

GOTHENBURG, Sweden, September 12, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the company has terminated the liquidity guarantee agreement with Pareto Securities. The agreement expires on September 13, 2024.

The purpose of a liquidity guarantee agreement is to improve share liquidity and reduce volatility. Isofol deems that the trading and liquidity of the company share is adequate and therefore, the need for a liquidity guarantee agreement is limited.

For more information, please contact

Isofol Medical AB (publ)

Petter Segelman Lindqvist, Chief Executive Officer

E-mail: petter.s.lindqvist@isofolmedical.com

Phone: +46 (0) 739 60 12 56

The information was submitted for publication, through the agency of the contact persons set out above, at 13:30 CEST on September 12, 2024.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company's drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin's efficacy. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com